Biotech Archives - Page 663 of 733

3 minute read

Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During ‘Spotlight on the Clinic’ Virtual Event

September 12, 7:06 AM

- Presentation and Discussion with Two Leading Neuromuscular Disease Experts - - Data from DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Anticipated in the Second Half of 2023 - - Refined Focus on

DYN

3 minute read

Allakos Announces Initiation Of Phase 2b Clinical Trial Of Subcutaneous Lirentelimab In Chronic Spontaneous Urticaria

By Benzinga Newsdesk

September 12, 7:04 AM

Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced it has initiated a Phase 2b clinical trial to

ALLK

1 minute read

Can-Fite Reports New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented By KOL Dr. Papp At The 31st European Academy Of Dermatology

By Benzinga Newsdesk

September 12, 7:02 AM

Dr. Papp: "The safety results on Piclidenoson and its progressive effectiveness over the study period position it as unique among the current treatment options especially given the chronic nature of psoriasis

CANF

1 minute read

Keros Therapeutics Presents Additional Clinical Data From Its KER-012 Program And Preclinical Data From Its KER-050 Program At The American Society Of Bone And Mineral Research 2022 Annual Meeting

By Benzinga Newsdesk

September 12, 6:01 AM

Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from

KROS

1 minute read

Bristol Myers’ Deucravacitinib Scores FDA Approval For Plaque Psoriasis

By Vandana Singh

September 12, 6:00 AM

The FDA approved Bristol Myers Squibb Co’s (NYSE:BMY) Sotyktu (deucravacitinib), an allosteric tyrosine kinase 2 (TYK2) inhibitor, for moderate-to-severe plaque psoriasis…

AMGN

3 minute read

Important Biotech Catalysts For September 9, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

September 9, 5:47 PM

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to…

ADAP

1 minute read

Spectrum Gets FDA Nod For Febrile Neutropenia Candidate, Sees Commercial Launch In Q4 2022

By Ragothaman Srinivasan

September 9, 4:57 PM

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ: SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.

SPPI

1 minute read

With New Growth Avenues, Analysts Boost Price Targets For This Botox Competitor

By Vandana Singh

September 9, 3:10 PM

A major overhang has been lifted with the FDA approval of Revance Therapeutics Inc’s (NASDAQ:RVNC) Daxxify (DaxibotulinumtoxinA-lanm). The catalyst also provides a…

RVNC

1 minute read

Immunocore Shares Fall After Early Solid Cancer Trial Data Of TCR Therapy

By Vandana Singh

September 9, 1:11 PM

Immunocore Holdings plc (NASDAQ:IMCR) released initial Phase 1 data for the first off-the-shelf ImmTAC targeting PRAME, demonstrating that IMC-F106C is well…

IMCR

1 minute read

AstraZeneca-Merck’s Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer

By Vandana Singh

September 9, 12:40 PM

AstraZeneca plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK) announced long-term follow-up results from the Phase 3 PAOLA-1 and SOLO-1 trials in first-line…

AZN